Search Prime Grants

UG1HL109322

Cooperative Agreement

Overview

Grant Description
The Ohio State University Blood and Marrow Transplant Research Consortium
Awardee
Ohio State University
Funding Goals
THE DIVISION OF BLOOD DISEASES AND RESOURCES SUPPORTS RESEARCH AND RESEARCH TRAINING ON THE PATHOPHYSIOLOGY, DIAGNOSIS, TREATMENT, AND PREVENTION OF NON-MALIGNANT BLOOD DISEASES, INCLUDING ANEMIAS, SICKLE CELL DISEASE, THALASSEMIA, LEUKOCYTE BIOLOGY, PRE-MALIGNANT PROCESSES SUCH AS MYELODYSPLASIA AND MYELOPROLIFERATIVE DISORDERS, HEMOPHILIA AND OTHER ABNORMALITIES OF HEMOSTASIS AND THROMBOSIS, AND IMMUNE DYSFUNCTION. FUNDING ENCOMPASSES A BROAD SPECTRUM OF HEMATOLOGIC INQUIRY, RANGING FROM STEM CELL BIOLOGY TO MEDICAL MANAGEMENT OF BLOOD DISEASES AND TO ASSURING THE ADEQUACY AND SAFETY OF THE NATION'S BLOOD SUPPLY. PROGRAMS ALSO SUPPORT THE DEVELOPMENT OF NOVEL CELL-BASED THERAPIES TO BRING THE EXPERTISE OF TRANSFUSION MEDICINE AND STEM CELL TECHNOLOGY TO THE REPAIR AND REGENERATION OF HUMAN TISSUES AND ORGANS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.
Grant Program (CFDA)
93.837 - Cardiovascular Diseases Research
Awarding / Funding Agency
National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]
Place of Performance
Columbus, Ohio 432101280 United States
Geographic Scope
Single Zip Code
Related Opportunity
The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional) (RFA-HL-24-010)
Analysis Notes
Amendment Since initial award the End Date has been extended from 06/30/24 to 06/30/31 and the total obligations have increased 856% from $194,009 to $1,854,454.
Ohio State University was awarded The Ohio State University Blood and Marrow Transplant Research Consortium Cooperative Agreement UG1HL109322 worth $1,854,454 from National Heart Lung and Blood Institute in July 2017 with work to be completed primarily in Columbus Ohio United States. The grant has a duration of 14 years and was awarded through assistance program 93.837 Cardiovascular Diseases Research. The Cooperative Agreement was awarded through grant opportunity The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional).

Status
(Ongoing)

Last Modified 8/20/25

Period of Performance
7/26/17
Start Date
6/30/31
End Date
58.0% Complete

Funding Split
$1.9M
Federal Obligation
$0.0
Non-Federal Obligation
$1.9M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to UG1HL109322

Subgrant Awards

Disclosed subgrants for UG1HL109322

Transaction History

Modifications to UG1HL109322

Additional Detail

Award ID FAIN
UG1HL109322
SAI Number
UG1HL109322-107816510
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Awardee UEI
DLWBSLWAJWR1
Awardee CAGE
5QH98
Performance District
OH-03
Senators
Sherrod Brown
J.D. (James) Vance

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Heart, Lung, and Blood Institute, National Institutes of Health, Health and Human Services (075-0872) Health research and training Grants, subsidies, and contributions (41.0) $1,833,533 100%
Modified: 8/20/25